PL3856775T3 - Chimeryczny receptor antygenowy - Google Patents

Chimeryczny receptor antygenowy

Info

Publication number
PL3856775T3
PL3856775T3 PL19779542.0T PL19779542T PL3856775T3 PL 3856775 T3 PL3856775 T3 PL 3856775T3 PL 19779542 T PL19779542 T PL 19779542T PL 3856775 T3 PL3856775 T3 PL 3856775T3
Authority
PL
Poland
Prior art keywords
antigen receptor
chimeric antigen
chimeric
receptor
antigen
Prior art date
Application number
PL19779542.0T
Other languages
English (en)
Inventor
Martin PULÉ
Shaun CORDOBA
Simon Thomas
Shimobi ONUOHA
Wen CHEAN LIM
Biao MA
Mathieu FERRARI
Original Assignee
Autolus Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1815775.0A external-priority patent/GB201815775D0/en
Priority claimed from GBGB1902021.3A external-priority patent/GB201902021D0/en
Application filed by Autolus Limited filed Critical Autolus Limited
Publication of PL3856775T3 publication Critical patent/PL3856775T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
PL19779542.0T 2018-09-27 2019-09-26 Chimeryczny receptor antygenowy PL3856775T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1815775.0A GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor
GBGB1902021.3A GB201902021D0 (en) 2019-02-14 2019-02-14 Chimeric antigen receptor
PCT/GB2019/052726 WO2020065330A2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
PL3856775T3 true PL3856775T3 (pl) 2025-06-09

Family

ID=68084861

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19779542.0T PL3856775T3 (pl) 2018-09-27 2019-09-26 Chimeryczny receptor antygenowy

Country Status (20)

Country Link
US (3) US12049510B2 (pl)
EP (1) EP3856775B9 (pl)
JP (3) JP7458382B2 (pl)
KR (1) KR20210066865A (pl)
CN (2) CN118459606A (pl)
AU (1) AU2019348975B2 (pl)
CA (1) CA3113896A1 (pl)
CL (1) CL2021000736A1 (pl)
DK (1) DK3856775T3 (pl)
ES (1) ES3012752T3 (pl)
FI (1) FI3856775T3 (pl)
HU (1) HUE069503T2 (pl)
IL (1) IL281428B2 (pl)
MX (1) MX2021003636A (pl)
NZ (1) NZ773507A (pl)
PL (1) PL3856775T3 (pl)
PT (1) PT3856775T (pl)
SG (1) SG11202102781UA (pl)
WO (1) WO2020065330A2 (pl)
ZA (1) ZA202101495B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
AU2018311345A1 (en) * 2017-08-02 2020-02-27 Autolus Limited Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
ES3012752T3 (en) * 2018-09-27 2025-04-10 Autolus Ltd Chimeric antigen receptor
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2023023596A1 (en) * 2021-08-18 2023-02-23 The Trustees Of The University Of Pennsylvania Compositions and methods for chimeric antigen receptors specific to b cell receptors
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
UA99339C2 (ru) 2008-03-12 2012-08-10 Имклоун Ллк Антитело, которое специфично связывает человеческий tyrp1
JP6359520B2 (ja) 2012-04-11 2018-07-18 アメリカ合衆国 Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
PL3071223T3 (pl) 2013-11-21 2021-08-16 Autolus Limited Komórka
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
KR102523934B1 (ko) * 2014-07-24 2023-04-20 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MY192062A (en) 2014-12-05 2022-07-25 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016094881A2 (en) * 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016094304A2 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US20170362297A1 (en) 2014-12-19 2017-12-21 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
LT3560953T (lt) 2014-12-24 2024-05-10 Autolus Limited Ląstelė
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
CA2925589A1 (en) 2015-04-13 2016-10-13 Pfizer Inc. Chimeric antigen receptors targeting b-cell maturation antigen
WO2016187216A1 (en) 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
JP2018522833A (ja) * 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
BR112018070159A2 (pt) 2016-04-01 2019-04-30 Kite Pharma, Inc. moléculas de ligação de bcma e métodos de uso das mesmas
CN105777911B (zh) 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
WO2018157147A1 (en) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
JP7710644B2 (ja) * 2017-10-12 2025-07-22 アイセル・ジーン・セラピューティクス・インコーポレイテッド 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
ES3003809T3 (en) 2017-11-01 2025-03-11 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
GB201801831D0 (en) 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
CA3106612A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with bcma specificity and uses thereof
ES3012752T3 (en) * 2018-09-27 2025-04-10 Autolus Ltd Chimeric antigen receptor
AU2020350769A1 (en) * 2019-09-20 2022-03-31 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3856775B9 (en) 2025-01-22
IL281428B2 (en) 2024-10-01
AU2019348975A1 (en) 2021-03-25
IL281428B1 (en) 2024-06-01
CN112771076A (zh) 2021-05-07
KR20210066865A (ko) 2021-06-07
EP3856775A2 (en) 2021-08-04
EP3856775B1 (en) 2024-10-30
ZA202101495B (en) 2024-06-26
HUE069503T2 (hu) 2025-03-28
NZ773507A (en) 2025-09-26
US20220033509A1 (en) 2022-02-03
JP7594067B2 (ja) 2024-12-03
CL2021000736A1 (es) 2021-08-20
JP2022502036A (ja) 2022-01-11
AU2019348975B2 (en) 2025-05-22
SG11202102781UA (en) 2021-04-29
JP2024178295A (ja) 2024-12-24
DK3856775T3 (da) 2025-02-03
US20220356260A1 (en) 2022-11-10
MX2021003636A (es) 2021-07-21
WO2020065330A3 (en) 2020-05-14
JP7458382B2 (ja) 2024-03-29
CN118459606A (zh) 2024-08-09
CN112771076B (zh) 2024-04-02
BR112021004986A2 (pt) 2021-06-08
IL281428A (en) 2021-04-29
ES3012752T3 (en) 2025-04-10
US12049510B2 (en) 2024-07-30
JP2023169370A (ja) 2023-11-29
US12454578B2 (en) 2025-10-28
CA3113896A1 (en) 2020-04-02
WO2020065330A2 (en) 2020-04-02
PT3856775T (pt) 2025-01-31
US20250277047A1 (en) 2025-09-04
FI3856775T3 (fi) 2024-12-04

Similar Documents

Publication Publication Date Title
SG11202102781UA (en) Chimeric antigen receptor
IL276396B2 (en) Chimeric antigen receptors against CD70
IL254254B (en) chimeric antigen receptor
GB201807870D0 (en) A CD79-specific chimeric antigen receptor
GB201607968D0 (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL277946A (en) Chimeric antigen receptors for the interleukin-23 receptor
IL289899A (en) Anti-hk2 chimeric antigen receptor (car)
GB201709508D0 (en) Chimeric antigen receptor
GB201801831D0 (en) Chimeric receptor
IL278992A (en) Chimeric antigen receptor T cell therapy
GB201807862D0 (en) Chimeric antigen receptor
GB201519900D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
GB201815775D0 (en) Chimeric antigen receptor
GB201809773D0 (en) Chimeric antigen receptor
GB201807866D0 (en) Chimeric antigen receptor
GB201906406D0 (en) Chimeric antigen receptor
GB201902021D0 (en) Chimeric antigen receptor
HK40038585A (zh) 嵌合抗原受体
GB201908239D0 (en) Chimeric antigen receptors
HK40043730A (en) Cd83-binding chimeric antigen receptors